Acetyl-L-Carnitine (ALCAR)
A 2003 meta-analysis of double-blind RCTs (Montgomery et al.) found a modest but significant advantage for ALCAR over placebo in mild cognitive impairment and mild Alzheimer's disease at 1.5–3g/day, apparent by 3 months and growing over time. A 2018 meta-analysis of 12 RCTs (Veronese et al., n=791) found a large reduction in depressive symptoms, comparable to antidepressants with fewer adverse effects, most clearly in older adults. A 2022 RCT in pre-frail older adults (3g/day) improved MMSE and walking distance. A 2020 critical review still calls its role in dementia "under debate". No healthy-young-adult trial was found.
Evidence reviewed:
Mechanism of action
Acetyl-L-Carnitine (ALCAR) is an acetylated form of L-Carnitine that crosses the blood-brain barrier more effectively than plain L-Carnitine. It works via three mechanisms: (1) donating acetyl groups for acetylcholine synthesis, supporting cholinergic neurotransmission; (2) transporting long-chain fatty acids into mitochondria for beta-oxidation, providing cellular energy to neurons; (3) supporting mitochondrial membrane integrity and reducing oxidative damage in aging neurons.
Clinical evidence summary
A 2003 meta-analysis of double-blind RCTs (Montgomery et al.) found a modest but significant advantage for ALCAR over placebo in mild cognitive impairment and mild Alzheimer's disease at 1.5–3g/day, apparent by 3 months and growing over time. A 2018 meta-analysis of 12 RCTs (Veronese et al., n=791) found a large reduction in depressive symptoms, comparable to antidepressants with fewer adverse effects, most clearly in older adults. A 2022 RCT in pre-frail older adults (3g/day) improved MMSE and walking distance. A 2020 critical review still calls its role in dementia "under debate". No healthy-young-adult trial was found.
Human effect matrix
Based on human clinical trials only. Animal and in-vitro data excluded.
| Effect | Evidence | Magnitude | Studies |
|---|---|---|---|
| Cognitive Function (MCI/Aging) | strong | Moderate | 2 |
| Mental Energy & Fatigue | moderate | Moderate | 1 |
| Mood & Depression | moderate | Large | 1 |
| Neuroprotection | preliminary | Small | 2 |
Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results
Documented benefits
- Cognition in mild cognitive impairment and mild Alzheimer's (modest effect)
- Fewer depressive symptoms, especially in older adults
- Acetylcholine precursor
Side effects & cautions
- Bipolar disorder: listed among agents associated with triggering manic or hypomanic episodes (case-report-level evidence) — avoid without psychiatric advice
- ADHD: rated "not supported" by the 2022 WFSBP/CANMAT nutraceutical guidelines — do not use as an ADHD treatment
- Fishy body odour at high doses (TMAO pathway)
- GI discomfort
- Insomnia if taken late
- Rare: increased agitation in some individuals
How to take
Stacking recommendations
Ingredients that pair well with Acetyl-L-Carnitine (ALCAR) and why.
ALCAR provides acetyl groups; Alpha-GPC provides choline. Together they support acetylcholine synthesis from both the acetyl and choline substrate sides.
Both support cholinergic function via different pathways. Citicoline provides CDP-choline for membrane repair; ALCAR provides mitochondrial energy and acetyl groups.
ALCAR protects existing neurons via mitochondrial support; Lion's Mane promotes new neuronal growth via NGF. Complementary maintenance + growth strategy.
Frequently asked questions
ALCAR vs plain L-Carnitine — what is the difference?
The acetyl group on ALCAR allows it to cross the blood-brain barrier and donate acetyl groups for acetylcholine synthesis. Plain L-Carnitine primarily acts in muscles and peripheral tissue for fat metabolism. For brain benefits, ALCAR is required — plain L-Carnitine will not produce cognitive effects.
Does ALCAR raise TMAO levels?
Yes, carnitine (including ALCAR) is metabolised by gut bacteria into trimethylamine, which the liver converts to TMAO. Elevated TMAO is associated with cardiovascular risk in observational studies. The clinical significance at standard ALCAR supplement doses (1.5–3g/day) is debated. If you have existing cardiovascular concerns, discuss with your doctor.
Is ALCAR useful for young healthy adults?
Unproven. The evidence is for older adults with cognitive decline or depressive symptoms; our 2026 review found no trial in healthy young adults. It is not a first-line nootropic for healthy young people — L-theanine + caffeine has stronger acute evidence. It is also not supported for ADHD.
Can ALCAR help with brain fog?
Possibly. ALCAR supports mitochondrial energy production in neurons, which may address brain fog caused by metabolic insufficiency. Anecdotal reports are common but controlled evidence specifically for "brain fog" in healthy adults is limited. If brain fog persists, investigate underlying causes (sleep, thyroid, iron levels) rather than relying solely on supplements.
Top stacks containing Acetyl-L-Carnitine (ALCAR)
Acetyl-L-Carnitine (ALCAR) in Southeast Asia
Products in Southeast Asia
HSA / NPRA / BPOM / FDA PH / Thai FDA
SEA country guides
Regulatory note
Health supplements in Singapore are regulated by the Health Sciences Authority (HSA); in Malaysia by the National Pharmaceutical Regulatory Agency (NPRA); in Indonesia by the Badan Pengawas Obat dan Makanan (BPOM); in the Philippines by FDA Philippines; in Thailand by FDA Thailand. Halal certification is required by law for supplements marketed to Indonesian consumers from 18 October 2026, regulated by the Badan Penyelenggara Jaminan Produk Halal (BPJPH); in Malaysia, products described as halal must be certified, with the Jabatan Kemajuan Islam Malaysia (JAKIM) as the certifying body. We surface certification status per product where verifiable. This page is editorial, not medical advice. Consult a qualified healthcare professional before starting any supplement.
Sources (8)expand
- PMID 12598816Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease (2003)
- PMID 29076953Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis (Veronese et al., 2018) (2018)
- PMID 2201659Acetyl-L-carnitine in the treatment of mildly demented elderly patients (1990)
- PMID 36043711Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial (2022)
- PMID 32408706Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update (2020)
- PMID 38875437Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial (2024)
- PMID 36940629Triggers for acute mood episodes in bipolar disorder: A systematic review. (2023)
- PMID 35311615Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. (2022)